Works matching IS 23744677 AND DT 2023 AND VI 9 AND IP 1
Results: 105
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00606-2
- By:
- Publication type:
- Article
Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00602-6
- By:
- Publication type:
- Article
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00591-6
- By:
- Publication type:
- Article
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00604-4
- By:
- Publication type:
- Article
Post-diagnosis weight trajectories and mortality among women with breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00603-5
- By:
- Publication type:
- Article
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00601-7
- By:
- Publication type:
- Article
Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00600-8
- By:
- Publication type:
- Article
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00587-2
- By:
- Publication type:
- Article
PI3K/AKT signaling activates HIF1α to modulate the biological effects of invasive breast cancer with microcalcification.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00598-z
- By:
- Publication type:
- Article
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00597-0
- By:
- Publication type:
- Article
Prediction models for hormone receptor status in female breast cancer do not extend to males: further evidence of sex-based disparity in breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00599-y
- By:
- Publication type:
- Article
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00595-2
- By:
- Publication type:
- Article
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00594-3
- By:
- Publication type:
- Article
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00592-5
- By:
- Publication type:
- Article
Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00585-4
- By:
- Publication type:
- Article
Adipose-enriched peri-tumoral stroma, in contrast to myofibroblast-enriched stroma, prognosticates poorer survival in breast cancers.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00590-7
- By:
- Publication type:
- Article
TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00588-1
- By:
- Publication type:
- Article
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00589-0
- By:
- Publication type:
- Article
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00584-5
- By:
- Publication type:
- Article
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00561-y
- By:
- Publication type:
- Article
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00583-6
- By:
- Publication type:
- Article
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00586-3
- By:
- Publication type:
- Article
Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutants.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00582-7
- By:
- Publication type:
- Article
Deep learning model improves tumor-infiltrating lymphocyte evaluation and therapeutic response prediction in breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00577-4
- By:
- Publication type:
- Article
Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00585-4
- By:
- Publication type:
- Article
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00580-9
- By:
- Publication type:
- Article
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00579-2
- By:
- Publication type:
- Article
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00578-3
- By:
- Publication type:
- Article
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00572-9
- By:
- Publication type:
- Article
Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00576-5
- By:
- Publication type:
- Article
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00571-w
- By:
- Publication type:
- Article
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00568-5
- By:
- Publication type:
- Article
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00574-7
- By:
- Publication type:
- Article
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00573-8
- By:
- Publication type:
- Article
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00579-2
- By:
- Publication type:
- Article
Impact of a risk based breast screening decision aid on understanding, acceptance and decision making.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00569-4
- By:
- Publication type:
- Article
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00571-w
- By:
- Publication type:
- Article
CBD-oil as a potential solution in case of severe tamoxifen-related side effects.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00570-x
- By:
- Publication type:
- Article
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00563-w
- By:
- Publication type:
- Article
Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity?
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00566-7
- By:
- Publication type:
- Article
RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00564-9
- By:
- Publication type:
- Article
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00562-x
- By:
- Publication type:
- Article
Spatial immunophenotypes orchestrate prognosis in triple-negative breast cancer with Miller-Payne grade 4 following neoadjuvant chemotherapy.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00565-8
- By:
- Publication type:
- Article
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00560-z
- By:
- Publication type:
- Article
Rare subtypes of triple negative breast cancer: Current understanding and future directions.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00554-x
- By:
- Publication type:
- Article